Orchestra BioMed Holdings Inc. (OBIO) — Cash Flow-to-Debt Ratio

Latest as of March 2026: -0.45x

Orchestra BioMed Holdings Inc. (OBIO) has a Cash Flow-to-Debt Ratio of -0.45x as of March 2026, meaning its operating cash flow of $-22.17 Million could theoretically repay 0% of its total liabilities ($49.69 Million) in one year. Explore Orchestra BioMed Holdings Inc. strategic investment ratio to see how much of total assets are deployed in long-term investments.

CF-to-Debt Ratio

-0.45x
Operating CF / Total Liabilities

Operating Cash Flow

$-22.17 Million
USD

Total Liabilities

$49.69 Million
USD

Data as of

Mar 2026
Most recent filing

Orchestra BioMed Holdings Inc. Cash Flow-to-Debt Ratio (2020–2025)

Historical debt coverage capacity for Orchestra BioMed Holdings Inc. across 6 annual periods. Also explore Orchestra BioMed Holdings Inc. (OBIO) total assets for the complete picture of this company's asset base.

Annual Cash Flow-to-Debt Ratio for Orchestra BioMed Holdings Inc. (2020–2025)

Year-by-year debt coverage analysis for Orchestra BioMed Holdings Inc.. For market capitalisation and broader financial context, see Orchestra BioMed Holdings Inc. (OBIO) total market value.

Year CF-to-Debt Ratio Operating CF (USD) Total Liabilities YoY Change
2025 -0.95x $-48.96 Million $51.48 Million ▲ +18.7%
2024 -1.17x $-50.56 Million $43.22 Million ▲ +31.1%
2023 -1.70x $-46.13 Million $27.17 Million ▼ -149.5%
2022 -0.68x $-29.29 Million $43.04 Million ▼ -196.9%
2021 -0.23x $-19.43 Million $84.76 Million ▲ +24.2%
2020 -0.30x $-26.18 Million $86.63 Million
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.